Nanobiotix Logo

Nanobiotix

Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.

NANO | PA

Overview

Corporate Details

ISIN(s):
FR0010102145 (+2 more)
LEI:
969500667RSYIH8YL895
Country:
France
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix is a late-stage clinical biotechnology company pioneering the development and commercialization of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose and efficacy of radiotherapy within cancer cells, aiming to enhance tumor destruction while sparing surrounding healthy tissue. This approach may also prime an immune response against metastatic tumors. Nanobiotix has a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, to co-develop and commercialize NBTXR3, with an initial focus on head, neck, and lung cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:41
Major Shareholding Notification
Franchissement de seuil
French 125.2 KB
2025-11-13 18:16
Regulatory News Service
Franchissement de seuil
French 277.7 KB
2025-11-13 17:45
Regulatory News Service
Franchissement de seuil
French 126.3 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS …
French 112.2 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 113.6 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright g…
French 93.9 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment …
English 69.0 KB
2025-08-11 11:29
Major Shareholding Notification
Franchissements de seuils
French 111.3 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-07-11 11:11
Major Shareholding Notification
Franchissement de seuils
French 122.5 KB
2025-06-20 15:17
Major Shareholding Notification
Franchissement de seuils
French 123.1 KB
2025-06-20 15:07
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d’actions c…
French 110.8 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 112.0 KB
2025-05-28 08:00
Regulatory News Service
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global …
French 91.4 KB

Automate Your Workflow. Get a real-time feed of all Nanobiotix filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-05-11 N/A Other Other 959,060 N/A

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.